Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with Braftovi in combination with cetuximab and chemotherapy. The approval was supported by data from Pfizer’s Phase 3 BREAKWATER trial. Guardant stated this is the first FDA-approved companion diagnostic for Guardant360 CDx in colorectal cancer.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health announces multi-year strategic agreement with Merck
- Guardant Health Announces Strong 2025 Preliminary Revenue Growth
- Guardant Health price target raised to $120 from $100 at Stifel
- Guardant Health price target raised to $135 from $120 at Mizuho
- Guardant Health price target raised to $130 from $100 at TD Cowen